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Recent genetic admixture coupled with striking differences in incidence of estrogen
receptor (ER) breast cancer subtypes, as well as severity, between women of African and
European ancestry, provides an excellent rationale for performing admixture mapping
in African American women with breast cancer risk. We performed the largest breast
cancer admixture mapping study with in African American women to identify novel
genomic regions associated with the disease. We conducted a genome-wide admixture
scan using 2,624 autosomal ancestry informative markers (AIMs) in 3,629 breast
cancer cases (including 1,968 ER-positive, 1093 ER-negative, and 601 triple-negative)
and 4,658 controls from the African American Breast Cancer Epidemiology and
Risk (AMBER) Consortium, a collaborative study of four large geographically different
epidemiological studies of breast cancer in African American women. We used an
independent case-control study to test for SNP association in regions with genome-
wide significant admixture signals. We found two novel genome-wide significant regions
of excess African ancestry, 4p16.1 and 17q25.1, associated with ER-positive breast
cancer. Two regions known to harbor breast cancer variants, 10q26 and 11q13, were
also identified with excess of African ancestry. Fine-mapping of the identified genome-
wide significant regions suggests the presence of significant genetic associations with
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ER-positive breast cancer in 4p16.1 and 11q13. In summary, we identified three novel
genomic regions associated with breast cancer risk by ER status, suggesting that
additional previously unidentified variants may contribute to the racial differences in
breast cancer risk in the African American population.
Keywords: breast cancer, African American women, admixture mapping, genetics, fine-mapping
INTRODUCTION
A majority of the close to 100 breast cancer risk loci that
have been identified to date were found using genome-
wide approaches in populations of European ancestry women
(Maxwell and Nathanson, 2013; Michailidou et al., 2015; Couch
et al., 2016). Follow-up studies in non-European populations are
necessary to understand the population-specific risk associated
with these loci. Further, genome-wide associations studies in
non-European populations are required to identify race-specific
genetic variation associated with breast cancer subtypes (Feng
et al., 2014). Sample size remains one of the main limiting
factors in performing genome-wide association studies (GWAS)
in non-Europeans. Admixture mapping, a method for discovery
of genomic regions that is based on linkage disequilibrium
in populations with recent population admixture, requires far
fewer samples and markers than GWAS to detect loci associated
with phenotypic variation (Rosenberg et al., 2003; Smith and
O’Brien, 2005; Winkler et al., 2010). Early admixture mapping
efforts in African American women with breast cancer were
likely under-powered, in particular to detect loci associated with
breast cancer subtypes (Fejerman et al., 2009). However, this
approach, in conjunction with fine mapping, has been successful
at identifying genetic associations with other complex traits in
recently admixed populations (Zhu et al., 2005; Freedman et al.,
2006; Nalls et al., 2008; Manuck et al., 2011; Bensen et al., 2014;
Jeff et al., 2014; Parker et al., 2014).
African American women have higher breast cancer mortality
rates than US women of European ancestry, particularly among
younger women, attributable to diagnosis at a later stage often
with larger tumors and lymph node metastases (Chlebowski
et al., 2005; Hershman et al., 2005; Grann et al., 2006; Fejerman
and Ziv, 2008). In addition, women of African ancestry are at
greater risk of having estrogen receptor negative (ER−) and
triple negative (ER−, progesterone receptor negative, PR−; and
human epidermal growth factor receptor 2 negative, HER2−)
breast cancer at all ages compared with European American
women (DeSantis et al., 2014). ER− and triple negative cancers
are more aggressive, and have fewer treatment options than
ER+ disease (Clarke et al., 2012). These differences in incidence,
severity and mortality between women of African and European
ancestry suggest that there may be different underlying genetic
contributions to breast cancer risk in African American and
European American women. Recent genetic admixture coupled
with these striking racial differences provides excellent rationale
for performing admixture mapping in African American women
with breast cancer.
To this end, we performed a genome-wide admixture mapping
in germline DNA in the African American Breast Cancer
Epidemiology and Risk (AMBER) Consortium, a collaborative
project from four of the largest studies of breast cancer in
African American women (Palmer et al., 2014a). This represents
the largest breast cancer admixture mapping study in African
American women to date. We discuss our findings in the context
of those from the previous admixture mapping study of breast
cancer (Fejerman et al., 2009) and of known breast cancer risk
loci identified among European Americans recently confirmed in
African Americans.
MATERIALS AND METHODS
Ethics Approval and Consent to
Participate
The CBCS was approved by the Institutional Review Board
at the University of North Carolina at Chapel Hill School of
Medicine. The WCHS was approved by the Institutional Review
Boards at the University of Medicine and Dentistry of New Jersey
(presently Rutgers University), Mount Sinai School of Medicine,
and Roswell Park Cancer Institute. The BWHS was approved by
the Institutional Review Board at the Boston University School
of Medicine. The MEC was approved by the Institutional Review
Boards of the University of Hawaii and University of Southern
California. Written informed consent was obtained from each
participant.
Study Population
Two case-control studies, the Carolina Breast Cancer Study
(CBCS) and the Women’s Circle of Health Study (WCHS),
and two prospective cohort studies, the Black Women’s Health
Study (BWHS) and the Multi-Ethnic Cohort (MEC) comprise the
AMBER Consortium (Palmer et al., 2014a,b; Bandera et al., 2015);
the four studies are described below.
The CBCS is a population-based case control study of women
ages 20–74, conducted in 44 counties in North Carolina that
began in 1993 (Newman et al., 1995). Breast cancer cases were
identified using Rapid Case Ascertainment in cooperation with
the NC Central Cancer Registry. Controls were identified using
Division of Motor Vehicles lists (for women under age 65) and
Health Care Financing Administration lists (for women 65 and
older). The age range of study participants was 20–74 years. CBCS
contributed 1,408 African–American cases and 615 controls to
this analysis.
The WCHS includes both European and African American
women, 20–75 years of age, newly diagnosed with a first primary,
and histologically confirmed breast cancer. Cases were identified
from 10 counties in New Jersey through the New Jersey State
Cancer Registry and through major metropolitan hospitals in
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New York City serving a large minority population. Controls,
frequency matched to cases by 5-years age categories and self-
reported race, were identified using random digit dialing in
New York City and New Jersey, as well as from the community
(Ambrosone et al., 2009; Bandera et al., 2013). Recruitment in
New York City took place between 2003 and 2008. Recruitment
at New Jersey started in 2006 and is ongoing. WCHS contributed
821 African American breast cancer cases and 834 African
American controls to this analysis.
The BWHS is an ongoing prospective cohort study of 59,000
US women aged 21–69 years from across the United States who
self-identify as “black” (Rosenberg et al., 1995). Beginning in
1995, women completed a 14-page postal health questionnaire.
Biennial postal questionnaires are mailed to participants to
update information. During 2004–2007, we obtained saliva
samples as a source of DNA from 26,814 participants using
the mouthwash-swish method (Cozier et al., 2004). BWHS
contributed 901 cases and 2,249 controls to this analysis.
The MEC study is a prospective cohort that includes over
215,000 individuals from Hawaii and California (primarily Los
Angeles) assembled between 1993 and 1996 (Kolonel et al., 2000;
Pike et al., 2002). African Americans, Native Hawaiians, Japanese,
Latinos and European Americans comprise the predominant
population. Blood samples were collected from incident breast
cancer cases starting in 1994 and identified by cohort linkage to
Surveillance, Epidemiology and End Results (SEER) registries, as
well as a random sample of MEC participants to serve as controls
for genetic analyses. MEC contributed genetic data from 499
African American cases and 960 African American controls to
this analysis.
Genotyping and Quality Control
Genotyping of constitutional DNA of CBCS, WCHS, and BWHS
samples was performed by the Center for Inherited Disease
Research (CIDR) using the Illumina Human Exome Beadchip
v1.1 array with custom content. The standard content of this
array includes more than 240,000 coding variants, as well as tag
SNPs for GWAS hits, a grid of common variants, and ancestry
informative markers (AIMs). A more complete description of
the exome chip design and standard content is available from
http://genome.sph.umich.edu/wiki/Exome_Chip_Design.
Genotype quality control for this study has been described
previously (Laurie et al., 2010). Genotype data were available
for 2,624 autosomal AIMs (Supplementary Table 1) included
as standard content in the exome array and typed in AMBER
participants, including 3,130 cases, 1,674 ER+ cases and 963 ER−
cases (515 triple negative) and 3,698 controls. In addition, genetic
data from 499 cases (130 ER− including 86 triple negative, 294
ER+, 75 ER unknown) and 960 controls in the MEC study were
available from previous genotyping on an earlier version of the
exome array that contained the same AIMs. Final sample size for
the current admixture analyses was 8,287 participants: 3,629 cases
(1,093 ER− including 601 triple negative, 1,968 ER+, and 568 ER
status unknown) and 4,658 controls.
We assessed population stratification by calculating principal
components of genetic variation using the smartpca program in
the EIGENSOFT package (Patterson et al., 2006). Supplementary
Figure 1 shows a plot of the top two principal components of
the participants stratified by study. No obvious differences in
distribution of these principal components were observed across
studies.
Admixture Mapping
We used ADMIXMAP software version 3.8.3103 (Hoggart et al.,
2004; Montana and Pritchard, 2004; Reich and Patterson, 2005)
to estimate African locus-specific ancestry and determine excess
sharing across the genome. ADMIXMAP uses a Markov chain
Monte Carlo algorithm to generate a score test at each position
in the genome that measures local ancestry associations with a
phenotype (Hoggart et al., 2004). Admixture mapping is generally
carried out using case-only and/or case-control analyses. The
case-only approach compares locus-specific ancestry in each
chromosomal position with average genome-wide ancestry.
The case-control method tests for differences of locus-specific
ancestry between cases and controls adjusting for individual
admixture and other covariates. Case-only analysis has greater
statistical power than case-control assuming that deviation in
ancestry between cases and controls is not due to population
stratification (Shriner, 2013). We therefore first performed a
case-only admixture scan and then a case-control admixture
analysis to confirm local ancestry associations from the case-
only results. Case-control analyses were adjusted for global
individual admixture, study, age (10-year groups), geographic
region, and source of constitutional DNA (Oragene-saliva, blood,
mouthwash-saliva). Statistical significance was assessed using Z
statistics, with a threshold of |Z| > 4.0 considered genome-
wide statistically significant. A negative Z-score indicates that
higher African (lower European) ancestry at that particular locus
is associated with higher breast cancer risk while a positive Z-
score indicates that lower African (higher European) ancestry
is associated with higher breast cancer risk. We performed
analyses of breast cancer overall, and by ER and triple negative
status. For each analysis, we ran ADMIXMAP using 2,000 burn-
in iterations and 8,000 follow-on iterations. The percentage
of African ancestry for each individual was determined using
ADMIXMAP and compared across controls, all cases and by ER
status as well as by site, using logistic regression adjusting for the
covariates described above.
Association Analyses
In order to identify SNPs that may help explain any observed
association between local African ancestry and risk of breast
cancer regions meeting the genome-wide significant criterion
(|Z| > 4) in AMBER, fine-mapping analyses were performed
using typed and imputed data from the African American
Breast Cancer (AABC) consortium, which included participants
from six epidemiological studies (Chen et al., 2011, 2013) after
excluding MEC, WCHS, and CBCS subjects which were included
in AMBER. Regional association analyses were conducted in
2,114 cases (1,116 ER+, 591 ER−, and 407 unknown ER
status) and 1,911 controls typed on the Illumina Human1M-Duo
BeadChip [34] and imputed using MACH with HAPMAP2 as a
reference. Within each genome-wide significant admixture peak
a Bonferroni correction for the number of directly genotyped
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markers tested was used to determine statistical significance
(Palmer et al., 2016).
RESULTS
Table 1 shows the participant characteristics by study site in
cases and controls. A total of 3,629 breast cancer cases (1,968
ER+ cases, 1,093 ER− cases including 601 triple negative, and
568 unknown ER status) and 4,658 controls were included in
the present analysis. CBCS and WCHS cases had the highest
proportion of African ancestry (84.0%) and MEC the lowest
(78.0%). Mean African ancestry, adjusted for age, geographic
region, DNA source and study site was 81.3% for controls
and 81.2% for cases (P = 0.74 for difference of means).
A total of 2,624 autosomal AIMs were analyzed (Supplementary
Table 1).
Admixture Mapping
Table 2 shows the four genome-wide significant regions in case-
only analysis (|Z| ≥ 4, P < 6 × 10−5) that also had confirmatory
results in case-control analysis (|Z| ≥ 2.0, P < 0.05). We
identified two novel genome-wide significant regions, showing
evidence of excess African ancestry associated with ER+ breast
cancer on 4p16.3 and 17q25.1. The 10q26 and 11q13.2 regions
both contain SNPs previously identified in published GWAS of
breast cancer in European ancestry women (Hunter et al., 2007;
Turnbull et al., 2010), and fine-mapping efforts have identified
independent signals in African American women (Chen et al.,
2011).
Supplementary Table 2 contains admixture results for all
2,624 AIMs and breast cancer subtypes. Supplementary Table 3
shows admixture results with suggestive evidence of association,
defined as 4> |Z|≥ 3.5 in case-only and |Z|≥ 2.0 in case-control
analyses. Of these 13 suggestive regions, seven contain at least
one genome-wide significant marker previously associated with
breast cancer (Hindorff et al., 2015).
Association Analyses
We used an independent study (African American Breast
Cancer Consortium, AABC) to test for association of SNPs
in the admixture associated regions identified for ER+ and
overall breast cancer. We defined significant association at
P < 5.8 × 10−6 after Bonferroni correction for multiple testing
based on adjustment for the 8,653 typed markers included. AABC
does not have information about triple negative breast cancer,
thus we did not follow up the three regions showing suggestive
association with this subtype. We report on the most significant
associations in each genomic region identified in the admixture
mapping (Table 3; Supplementary Figure 2).
4p16 and ER-Positive (ER+) Breast Cancer
One SNP in the 4p16 region exceeded multiple test correction
threshold, rs112545418 in ZFYVE28; the A allele showed a 46%
risk increase compared to the G allele (P = 4.0 × 10−6).
Consistent with our admixture mapping results (i.e., excess of
local African ancestry at 4p16 associated with higher risk of ER+
breast cancer), the risk A-allele is more frequent in 1000 Genomes
African ancestry samples (AFR), 14%, and AABC, 13%, than in
European ancestry (EUR) samples, 1% (Table 3).
10q26 and Overall Breast Cancer
The most significant association with overall breast cancer,
rs12244041, at P = 2.9 × 10−6, is located over 10 Mb from the
well-known breast cancer associated FGFR2 gene and is unlinked
to SNPs in this region (r2 = 0.01). The risk T-allele at this SNP
is associated with 87% higher risk of breast cancer, and it is more
frequent in AABC (79%) and AFR populations (83%) compared
to EUR populations (68%) (Table 3). The frequency differences
by race are consistent with our admixture mapping results that
TABLE 1 | Characteristics of participants by study in the AMBER consortium.
Characteristic BWHS CBCS WCHS MEC Total
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls
Total 901 2249 1408 615 821 834 499 960 3629 4658
% African ancestrya 80.5 81.4 84.0 83.5 84.0 84.0 78.0 78.1 81.2 81.3
% Family historyb of breast cancer 15 9 18 11 16 12 21 13 17 11
ER status
ER+ 498 741 435 294 1968
ER− 233 565 165 130 1093
Triple negative 102 380 33 86 601
Unknown 170 102 221 75 568
Age at diagnosis
<40 47 204 85 0 336
40–49 262 459 215 9 945
50–59 302 381 292 108 1083
60–69 204 267 173 165 809
≥70 86 97 56 217 456
ER, estrogen receptor; BWHS, Black Women’s Health Study, CBCS, Carolina Breast Cancer Study, WCHS, Women’s Circle of Health Study, MEC, Multi-Ethnic Cohort.
aMean of individual African ancestry (%) adjusted for age, geographic region, DNA source, and study site. bFirst-degree family history of breast cancer.
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TABLE 2 | Genome wide significant regions of excess African ancestry (negative Z-score) and reduced (positive Z-score) associated with breast cancer
at |Z| > 4 in case-only analyses and corresponding case-control resultsa.
Locus All breast cancers ER+ breast cancers ER− breast cancers TNBC Breast cancer
GWAS SNPs
Zc/Zcc ORb (95% CI) Zc/Zcc ORb (95% CI) Zc/Zcc ORb (95% CI) Zc/Zcc ORb (95% CI)
4p16.3 −2.4/−0.9 1.05 (0.93–1.18) −4.1/−2.7 1.22 (1.06–1.41) 0.7/1.6 0.86 (0.72–1.02) 0.7/1.2 0.86 (0.68–1.09) –
10q26 −4.7/−2.1 1.12 (1.00–1.26) −3.3/−1.2 1.08 (0.94–1.24) −3.5/−1.7 1.16 (0.97–1.38) −1.5/−0.06 0.99 (0.79–1.26) rs11199914
rs3750817
rs35012336
rs10736303
rs2981579
rs2981578
rs2981575
rs1219648
rs1219642
rs2912774
rs2936870
rs2420946
rs2981582
rs2935717
11q13.2 3.9/1.9 0.91 (0.82–1.00) 4.8/3.1 0.83 (0.75–0.93) 0.5/−0.6 1.04 (0.90–1.21) −1.1/−1.5 1.16 (0.95–1.42) rs614367
rs3903072
rs537626
17q25.1 −3.8/−1.7 1.09 (0.98–1.22) −4.3/−2.6 1.20 (1.05–1.37) −0.2/0.7 0.93 (0.79–1.11) −0.6/−0.1 1.00 (0.80–1.26) –
a |Z| ≥ 4.0 case-only analysis results are presented only for regions with case-control results |Z| ≥ 2.0, P < 0.05. bOdds ratio and 95% confidence interval per African
allele estimated from the admixture mapping case-control analysis. Odd ratios were adjusted for individual African ancestry, study site, age, geographic region, and DNA
source. TNBC, triple negative breast cancer. Zc, Z-score from the case-only analysis. Zcc, Z-score from the case-control analysis.
TABLE 3 | Most significant single independent SNP associations in the African American Breast Cancer (AABC) consortium within genomic regions
identified in admixture mapping of AMBER.
Locus/Breast
Cancer subtype
Local African
ancestry
Position (bp) Allelesa OR (95% CI) P-value Effect allele frequency
AABC AFRb EURc
4p16, ER+ Excess
rs112545418 2279036 A/G 1.46 (1.24–1.72) 4.0 × 10−6 0.13 0.14 0.01
10q26, all breast cancer Excess
rs12244041 133275151 T/A 1.34 (1.21–1.46) 3.9 × 10−6 0.78 0.83 0.68
11q13, ER+ Deficit
rs77274510 61995513 A/G 3.13 (2.60–3.58) 5.8 × 10−6 0.012 < 0.01 0.059
rs117564384 62011320 A/G 2.97 (2.50–3.44) 6.8 × 10−6 0.012 < 0.01 0.051
rs116638271 67441627 G/A 2.31 (1.95–2.67) 4.7 × 10−6 0.97 0.97 1.0
17q25, ER+ Excess
rs55850050 74453990 T/C 1.55 (1.23–1.94) 1.6 × 10−4 0.062 0.027 0.16
aEffect allele/reference bAfrican ancestry populations from 1000 Genomes Project cEuropean ancestry populations from 1000 Genomes Project
excess of local African ancestry at 10q26 is associated with higher
risk of all breast cancer.
11q13 and ER+ Breast Cancer
Three variants, rs116638271 in ALDH3B2, rs77274510 in RP11-
703H8.9, and rs117564384 in SCGB1D2 in the chromosome
11q13 region were significantly associated with ER+ breast
cancer after correction for multiple testing (Table 3). The latter
two are only 15,807 bp apart and are in modest LD (r2 = 0.66)
in 1000 Genomes AFR populations, while rs116638271, resides
∼5.4 Mb from rs117564384 and is not correlated (r2 = 0) with
either SNP. In agreement with the admixture mapping results
(i.e., deficit of local African ancestry at 11q13 associated with
higher risk of ER+ breast cancer) the risk alleles of the three SNPs
were less frequent in 1000 Genomes AFR vs. EUR populations
(Table 3). For rs77274510 and rs117564384, the risk alleles had
<1% frequency in 1000 Genomes AFR subjects compared to
5.9 and 5.1%, respectively, in EUR samples. For rs116638271
the risk allele had 97% frequency in AFR vs. 100% in EUR. In
other words, the protective rs116638271 allele against ER+ breast
cancer seems to be specific of AFR populations with a frequency
of about 3% but 0% in EUR populations.
The genome wide significant ER+ associated region on
chromosome 11 was also suggestive of association in the
admixture analyses of overall breast cancer (Z = 3.9 in case-only
analysis, and Z = 1.9 with P = 0.058 in case-control analysis).
This region contains three overall breast cancer associated
variants within an 8.6 Kb region, rs75313515 (P = 2.4 × 10−6),
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rs75771004 (P = 3.2× 10−6) and rs116667969 (P = 3.5× 10−6)
that are significant after correction for multiple testing. The
first two SNPs are in strong LD while rs116667969 is very
weakly correlated with both SNPs (r2 ∼0.40). The minor alleles
range from 2.5 to 4% in our analyses; however, none of the
variant alleles at these three SNPs are present in the EUR 1000G
populations. These three SNPs are within 10 Kb of rs116638271
(r2 = 0.40), one of the three SNPs under this peak shown to
be associated with ER+ breast, which suggests that this region
contains multiple independently associated variants.
17q25 and ER+ Breast Cancer
No single variant was significantly associated with ER+ breast
cancer after correction for multiple testing. The risk T-allele,
at rs55850050, the most significant SNP in the chromosome 17
region, conferred a 55% increased susceptibility to ER+ breast
cancer (P = 1.6 × 10−4). The direction of the risk was contrary
to what was expected based on the admixture results (i.e., excess
of local African ancestry at 17q25 associated with higher risk of
ER+ breast cancer), as the risk T-allele was less frequent in 1000
Genomes AFR (2.7%) vs. EUR populations (16.1%) (Table 3).
Notably it resides adjacent to BRCA1 (17q21.1) and 13 Mb from
the 17q23.1 region which contains breast cancer susceptibility
SNPs (Ahmed et al., 2009; Kelemen et al., 2009; Lin et al., 2012).
Regions of Suggestive Genome-Wide
Significance
Overall Breast Cancer
The 9q34 region showed excess local African ancestry associated
with risk of overall breast cancer (Supplementary Table 3).
It does not harbor known susceptibility breast cancer variants
and no SNPs were associated with overall breast cancer at
nominal P < 0.05. This region contains multiple Crohn’s disease,
ulcerative colitis and Type 2 diabetes loci (Supplementary
Table 4).
ER+ Breast Cancer
We found an excess of local African ancestry in the chromosome
region 8q24 associated with ER-positive breast cancer
(Supplementary Table 3). The 8q24 locus contains breast cancer
susceptibility loci as well as loci for other cancers including
ovarian, prostate, colorectal, glioma, lymphomas and leukemias,
bladder and kidney (Supplementary Table 4). No single SNP
reached significance after correction for multiple testing.
Two SNPs, rs147582253 (P = 1.9 × 10−5) and rs10112657
(P = 5.8 × 10−5) showed suggestive associations with ER+
breast cancer. The direction of the associations were consistent
with the admixture mapping results, as the risk alleles of both
SNPs, rs147582253-G (1.7% in African vs. 0% in European
populations) and rs10112657-T (3.3% in African vs. 0% in
European populations), were more frequent in African ancestry
vs. European ancestry populations.
ER-Negative (ER−) Breast Cancer
We found three regions, 2q24, 5p13, and 18q23, showing
suggestive evidence of association with ER− breast cancer
(Supplementary Table 3); both 2q24 and 5p13 contain or are
adjacent to breast cancer susceptibility variants. The 2q24 region
showed a deficit of local African ancestry associated with ER−
breast cancer. The admixture signal in 2q24 is less than 4 Mb
from two recently identified SNPs, rs2016394, and rs1550623,
associated with breast cancer in European ancestry women in
the Collaborative Oncological Gene-Environment Study (COGS)
(Michailidou et al., 2013). However, these two variants are not
specific to ER− breast cancer (Michailidou et al., 2013); thus, they
do not explain the admixture signal in 2q24. Our fine-mapping
efforts found two independent signals associated with ER− breast
cancer. Both protective alleles, rs78550178-G (99% frequency in
African vs. 84% in European populations) and rs62172609-G
(76% frequency in African vs. 31% in European populations),
were more frequent in African ancestry vs. European ancestry
populations as expected according to the direction of the
admixture signal.
Region 5p15.33, showing excess African ancestry associations
with ER− breast cancer, contains the TERT gene, which harbors
a well-known ER− specific breast cancer associated variant,
rs10069690 (Haiman et al., 2011; Garcia-Closas et al., 2013;
Michailidou et al., 2013; Purrington et al., 2014). The T allele
of rs10069690 was our most significant association with ER−
breast cancer (P = 2.2 × 10−5). The T allele is far more
frequent in African populations (66%) versus Europeans (28%).
We found some evidence of one additional independent signal
in TERT, represented by the risk increasing C allele of rs37004
(P = 6.8 × 10−5, 99% frequency in AFR vs. 78% in EUR)
at ∼1 Mb from rs10069690. This variant has been shown to
be associated with lung cancer risk in the Genetic Association
and Mechanisms in Oncology (GAME-ON) consortium (Karami
et al., 2015).
The 18q23 region is novel and showed an excess of local
African ancestry associated with risk of ER− breast cancer,
however the most significantly associated single SNP, rs58839649
at P= 1.5× 10−4, did not pass multiple test correction; the minor
G-allele was associated with a 60% increased risk of ER- breast
cancer with a frequency in AABC of 10, 13% in AFR populations,
and absent in EUR populations. This region contains prostate
susceptibility SNPs (Eeles et al., 2013) and has been identified by
linkage analyses as a region co-segregating with familial Glioma
(Liu et al., 2012) (Supplementary Table 4).
Triple-Negative Breast Cancer
We found evidence of association of excess African ancestry with
triple negative disease at three locations: 2q37.1, 3p24.2, and
18p11 (Supplementary Table 3). While higher African ancestry
in the 2q37 and 3p24 loci seems to increase risk of ER− breast
cancer as well, higher African ancestry in the 18p11 locus appears
to be associated only with risk of triple negative breast cancer. The
3p24.2 region contains well-established breast cancer associated
SNPs (Matsumoto et al., 1997, 2000; Yang et al., 2001; Ahmed
et al., 2009; Lin et al., 2012). However, there are no reports of
variants at 2q37.1 or 18p11 associated with breast cancer or breast
cancer subtypes. Given these regions of excess African ancestry
are associated with disease; it may be possible that these locations
harbor breast cancer susceptibility alleles only present in African
ancestry populations.
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DISCUSSION
In this large genome-wide admixture scan in African
American women, we found evidence of associations
of local African ancestry with breast cancer in several
genomic regions. Tests of genetic associations in the
identified regions in an independent sample suggest that
continental ancestry specific genetic variation within
these regions may be associated with breast cancer
subtypes.
4p16 and ER-Positive Breast Cancer
This region contains no previously reported genome wide
significant breast cancer loci, but loci for bladder cancer,
as well as other traits and diseases include triglycerides
and cholesterol levels, bone mineral density, type 2 diabetes
and Parkinson’s disease (Supplementary Table 4).The most
strongly associated SNP in 4p16, rs112545418, in ZFYVE28,
was in moderate linkage disequilibrium (r2 = 0.48) with a
nearby variant rs17132398, associated with ER-positive breast
cancer at P = 1.8 × 10−4. Analysis of rs17132398 using
RegulomeDB database (Boyle et al., 2012) showed that this
SNP is located inside an enhancer region across multiple cell
lines, and is likely to affect binding of transcription factors
and expression of ZFYVE28, which is a negative regulator of
epidermal growth factor receptor (EGFR) signaling (Mosesson
et al., 2009). The low frequency of the rs112545418 risk
A-allele (1%) and the corresponding risk T-allele of rs17132398
(0.4%) in European ancestry populations may explain why
it has not been identified in previous GWAS of breast
cancer.
10q26 and Overall Breast Cancer
The 10q26 showed excess of local African ancestry associated
with risk of overall breast cancer and was our strongest admixture
association with overall breast cancer. This region contains well
established SNPs in FGFR2 associated with increased risk of
breast cancer (Chen et al., 2011). A recent fine-mapping of
FGFR2 (Meyer et al., 2013) identified three independent signals
in Europeans and East Asians: the first signal represented by
rs35054928, the second signal by rs45631563, and the third
one by rs2981578 (Meyer et al., 2013). The rs2981578 was
previously identified as the SNP with the strongest association
with overall and ER+ breast cancer in FGFR2 in African
Americans (Chen et al., 2011), and it was also shown recently
by us using AMBER consortium data (Ruiz-Narvaez et al.,
2016). Interestingly, the excess of African ancestry in breast
cancer cases extends over both FGFR2 and a second region
spanning from 131 to 134 Mb on chromosome 10. This second
region contains our significant variant, rs12244041 (Table 3;
Supplementary Figure 2), as well as a non-synonymous variant,
rs148966337, previously shown to be associated with both
overall and ER− breast cancer (Haiman et al., 2013). This is
a less common variant (1.9%) that was only present in the
African American women from the MEC study, but completely
absent in women of other continental ancestries (Haiman et al.,
2013).
11q13 and ER-Positive Breast Cancer
Although the chromosome 11q13 region has been previously
shown to contain breast cancer SNPs (Michailidou et al.,
2013; Ahsan et al., 2014), all three of the SNPs we found
within the admixture-identified region were independent
of the published GWAS-identified SNPs. One of the
three SNPs in the chromosome 11 region, rs117564384,
resides in SCGB1D2. SCGB1D2 expression is high in and
almost exclusive to mammary tissue (Culleton et al., 2007),
significantly differs between histologically normal breast
tissue and breast cancer tissue (Zubor et al., 2015), and it
also has been used as a marker to detect disseminated tumor
cells (DTC) in breast cancer (Brown et al., 2006; Lacroix,
2006).
In summary, this is the largest admixture analysis of African
American breast cancer, both in number of subjects and
markers, to date. One limitation of this report is the lack
of characterization of tumors by grade and stage that may
show differential association with locus-specific African ancestry.
Nevertheless, the current study includes more than twice the
number cases and a higher density of AIMs throughout the
genome compared to the previous admixture mapping of breast
cancer in AA women (Fejerman et al., 2009). In addition, the
use of controls in the present study allowed us to confirm
significant results from the case-only scan. Fine-mapping of
the identified regions showed that multiple genomic variants
may be within admixture associated regions. Our results suggest
that several loci with small to moderate effects rather than
a few with strong effects are responsible for the differences
of incidence of ER subtypes among US white and black
women.
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